UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 董事名單與其角色和職能 自二零二四年十一月一日起，聯康生物科技集團有限公司董事會（「董事會」）成員 載列如下： 獨立非執行董事 周啓明先生 任啓民先生 馬青山先生 以下提供各董事會成員於各董事委員會中所擔任職位的資料： 審核委員會 周啓明先生 （ 審核委員會主席 ） 任啓民先生 馬青山先生 薪酬委員會 周啓明先生 （ 薪酬委員會主席 ） 梁國龍先生 任啓民先生 馬青山先生 執行董事 梁國龍先生 （ 主席 ） 陳大偉先生 （ 副主席 ） 趙志剛先生 （ 行政總裁 ） 非執行董事 邱國榮先生 張清女士 提名委員會 梁國龍先生 （ 提名委員會主席 ） 周啓明先生 任啓民先生 馬青山先生 香港，二零二四年十一月一日 * 僅供識別 ...

聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 委任非執行董事及授出購股權 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就本公告全部或任 何部分內容而產生或因倚賴這些內容引起的任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 張女士所擁有的深厚醫藥行業背景及豐富的新藥投資和技術投資經驗，會為本公 司董事會在研發方面的決策提供更多的意見與支持。同時，張女士在美國的工作 履歷和資源，會為本公司拓展海外業務與國際化發展提供幫助。 除上文所披露者外，於本公告日期，張女士與本公司任何董事、高級管理層、主 要股東或控股股東（ 具有上市規則所賦予之涵義 ）概無任何關係。除上文所披露者 * 僅供識別 – 1 – 董事會宣佈，下列事項自二零二四年十一月一日起開始生效： 張清女士（「張女士」）已獲委任為非執行董事。 張女士之履歷詳情載列如下： 張清女士，37歲，自二零二零年至今擔任一家美國股權 ...

Financial Performance - Revenue for the six months ended June 30, 2024, reached approximately HKD 273.6 million, representing a year-on-year increase of 9.5% compared to HKD 249.9 million in 2023[4] - Gross profit for the same period was HKD 230.6 million, with a gross margin of 84.3%, up from 79.6% in the previous year[4] - Profit before tax surged by 64.9% to HKD 71.5 million, compared to HKD 43.4 million in the prior year[5] - The company achieved a significant operating profit of HKD 87.2 million, a 59.2% increase from HKD 54.7 million in the previous year[5] - The company recorded a record profit of approximately HKD 67.4 million, a significant year-on-year increase of 71.0%, with earnings per share reaching approximately HKD 1.09, reflecting a strong growth of 75.8%[32] - The total comprehensive income for the period was HKD 65,312,000, compared to HKD 30,013,000 in the prior year, reflecting a significant increase of 117.7%[71] - The net profit surged to approximately HKD 67.4 million, a remarkable increase of 71.0% from HKD 39.4 million in the first half of 2023[48] - The company reported a basic and diluted earnings per share of HKD 1.09 for the six months ended June 30, 2024, compared to HKD 0.62 in the same period of 2023, marking a 75.8% increase[71] Product Development and Launches - The company launched its fifth product, 博固泰*, in March 2024, contributing significantly to revenue growth[8] - The launch of Bogu Tai marks a new era in osteoporosis treatment, with sales expected to start in the first half of 2024 and a patient repurchase rate exceeding 65%[9] - The application for the launch of Diquafosol Sodium Eye Drops has been accepted, addressing the high demand in China's ophthalmic drug market, which has over 360 million dry eye patients[11] - The company is preparing for the fourth clinical study and real-world research of Bogu Tai, focusing on fracture prevention and pain relief, and plans to apply for FDA approval[10] - The company is focused on R&D in endocrinology, ophthalmology, and dermatology, with multiple patented biopharmaceuticals and high-value generics in various stages of development[12] - The second-generation Uni-PTH (Bogu Tai) is the first pre-filled injection pen in China, designed for high dosing accuracy and minimal injection pain, officially approved in January 2024[15] - The third-generation oral Uni-PTH is currently in data collection for preparation, while the microneedle version is under development[15] Market Trends and Opportunities - The biopharmaceutical industry in China saw the approval of 44 new drugs in 2024, including 23 innovative drugs, reflecting a favorable regulatory environment[6] - The medical aesthetics market in China is projected to grow from RMB 200 billion in 2023 to RMB 288 billion in 2024, driven by consumer demand and technological advancements[6] - The dry eye drug market is projected to exceed RMB 42 billion by 2030, with a compound annual growth rate of 28.4%[11] - The biopharmaceutical market in China is projected to grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2032, driven by technological advancements and an aging population[49] - The medical aesthetics market is expected to maintain a CAGR of 10% to 15% from 2024 to 2027, reflecting increasing consumer spending on beauty standards[49] Research and Development - Research and development expenses increased to HKD 23.3 million, accounting for 8.5% of revenue, down from 9.2% in the previous year[4] - The company has initiated multiple R&D projects, including epidermal growth factor hydrogel wound dressings and is continuing to focus on endocrine diseases, ophthalmology, and dermatology[45] - The company is committed to investing in specialized peptide formulation technologies, despite potential increases in R&D expenses, as these investments are deemed crucial for long-term value creation[52] - The company incurred research and development expenses of HKD 20,890,000 for the six months ended June 30, 2024, compared to HKD 11,740,000 in the same period of 2023, which is an increase of 78.1%[70] Financial Stability and Liquidity - The debt-to-equity ratio improved to 55.8%, down from 59.4% in the previous year, indicating better financial stability[4] - Cash ratio improved to 1.30 times, up from 1.13 times in the previous year, indicating enhanced liquidity[4] - As of June 30, 2024, the company's cash and bank deposits amounted to approximately HKD 153.96 million, with total assets of approximately HKD 487.09 million, reflecting an increase from HKD 409.99 million as of December 31, 2023[57] - The company has a debt-to-total-assets ratio of 35.8% as of June 30, 2024, a decrease from 37.3% as of December 31, 2023, indicating improved financial stability[57] Strategic Initiatives - The company has organized nearly 400 academic conferences and activities to promote osteoporosis prevention and treatment, benefiting over 1,000 patients through public welfare initiatives[9] - The company is establishing a specialized sales team to promote its products and expand its market presence in the medical aesthetics sector, aiming for annual revenue exceeding RMB 30 million from this division within the next 2 to 3 years[51] - The company has entered a strategic partnership with Chongqing Minji Medical Devices Co., Ltd. to expand into the medical beauty device market, gaining exclusive distribution rights for complementary products[55] - The company has established an official flagship store on JD.com and partnered with over 200 online distributors to expand its online presence, enhancing market coverage and sales efficiency[53] Shareholder Information - The company repurchased a total of 201,180,000 shares during the six months ended June 30, 2024, including 115,180,000 shares in the first half of the fiscal year[64] - The number of shares issued and fully paid decreased to 6,163,588,147 shares as of June 30, 2024, from 6,364,768,147 shares as of December 31, 2023, a decrease of 3.2%[173] - As of June 30, 2024, the largest shareholder, Automatic Result Limited, holds 1,650,971,464 shares, representing 26.40% of the total issued shares[184] Operational Highlights - The company has made significant progress in the construction of a new factory in Dongguan, Guangdong, which includes a 4,300 square feet GMP standard production building and two 1,300 square feet GMP standard warehouses, aiming to produce 19 million units annually with a projected annual revenue exceeding RMB 1 billion[54] - The company established a new production facility in Dongguan, enhancing the production capacity of the eye drop product, Diquafosol Sodium, which is expected to be approved for market launch in Q1 2025[30] - The company plans to complete BFS packaging research and filing by 2025, with the launch of BFS packaged products expected in 2026, enhancing product safety and convenience[54] Miscellaneous - The company did not declare any interim dividend for the six months ended June 30, 2024[66] - The company has not reported any significant impact on its financial position or performance due to the adoption of new accounting standards[87] - The interim report has been reviewed by the company's audit committee[194] - The interim report is published on the Hong Kong Stock Exchange and the company's website[194]

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of approximately HKD 273.6 million, representing a year-on-year increase of 9.5%[2] - The company's profit reached approximately HKD 67.4 million, a significant year-on-year increase of 71.0%[1] - The group achieved a revenue growth of 9.5% year-on-year, reaching approximately HKD 273.6 million in the first half of 2024[6] - The net profit surged by 71.0% year-on-year, amounting to approximately HKD 67.4 million during the same period[6] - The flagship product 金因肽® generated revenue of approximately HKD 91.3 million, a decrease of 4.8% due to stricter procurement strategies in public hospitals[28] - The chemical drug, Pinanop®, saw revenue growth of 12.8%, increasing from approximately HKD 124.8 million to approximately HKD 140.9 million, attributed to successful re-selection for centralized procurement[30] - The newly launched product, Bogu Tai®, achieved sales of HKD 18.8 million within four months of its release, exceeding initial expectations[32] - The group recorded revenue of approximately HKD 273.6 million, representing a year-on-year growth of 9.5%[34] - Gross profit increased to approximately HKD 230.6 million, up 16.0% from HKD 198.9 million in the same period last year, with a gross margin of 84.3%, an increase of 4.7 percentage points[37] - Operating profit for the six months ending June 30, 2024, was HKD 71.808 million, up 63.8% from HKD 43.822 million in the prior year[60] - The total comprehensive income for the period was HKD 65.312 million, compared to HKD 30.013 million in the prior year[60] Product Development and Launches - Sales from the PinaPro® product line increased by 12.8% year-on-year, driven by successful procurement renewals from hospitals[1] - The company launched the BoguTai® product in March 2024, generating sales of HKD 18.8 million within four months[1] - The company is set to officially launch its first premium skincare product, Skbrella™ FN, expected to contribute to sales in the second half of 2024[1] - The company received approval for the market listing of sodium hyaluronate eye drops in January 2024, marking significant progress in its ophthalmic product portfolio[1] - The application for the approval of sodium diquafosol eye drops was accepted in January 2024, addressing the high demand in the Chinese ophthalmic market[9] - Diquafosol sodium eye drops are expected to be approved for market launch in Q1 2025, complementing the company's strong ophthalmic product portfolio[25] - The company is developing a third-generation oral Uni-PTH and a microneedle version, with data collection currently underway[13] - The company is developing UB105, a new oral hypoglycemic agent that combines GLP-1/GIP/GCG receptor agonists for effective weight loss and improved glycemic control[16] - The company has launched new skincare ingredients, including collagen and beauty peptides, enhancing its product line in the skincare market[18] - The company is developing new skincare ingredients including collagen, beauty peptides, microbiome skincare products, and exosome products, leveraging research ecosystems and rich experience in the cosmetics field[19] Research and Development - Research and development expenses amounted to HKD 23.3 million, representing 8.5% of revenue, down from 9.2% in the previous year[2] - The group is committed to R&D in endocrinology, ophthalmology, and dermatology, with multiple patented biopharmaceuticals in various stages of development[10] - R&D expenses for the first half of 2024 were approximately HKD 20.9 million, a 77.9% increase compared to approximately HKD 11.7 million in the same period of 2023[39] - The company is focused on technological innovation and expanding its influence in the biopharmaceutical and high-end medical device sectors[50] - Advanced synthetic biology and hydrogel technology platforms are being utilized to enhance product development and drug delivery systems[46] Market Trends and Opportunities - The biopharmaceutical industry in China saw the approval of 44 new drugs in 2024, including 23 innovative drugs, indicating a favorable environment for the company's growth[4] - The dry eye medication market is projected to exceed RMB 42 billion by 2030, with a compound annual growth rate of 28.4%[9] - The pharmaceutical sector in China is expected to grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2032, driven by technological advancements and an aging population[43] - The medical beauty market is projected to maintain a CAGR of 10% to 15% from 2024 to 2027, fueled by increasing consumer spending on beauty standards[43] - The company is exploring opportunities in the medical beauty sector, anticipating annual revenue exceeding RMB 30 million from this division within the next 2 to 3 years[45] Financial Position and Assets - As of June 30, 2024, the company's cash and bank deposits amounted to approximately HKD 153,964,000, with total assets of about HKD 487,086,000[51] - The company's current liabilities as of June 30, 2024, were HKD 118,316,000, with a debt-to-asset ratio of 35.8%[51] - The company's net assets increased to HKD 312,653,000 in June 2024, up from HKD 257,174,000 in December 2023, indicating a growth of 21.6%[62] - The company reported a net cash used in investing activities of HKD (35,800,000) for the six months ended June 30, 2024, compared to HKD (19,721,000) in the same period of 2023, representing an increase in cash outflow of 81.5%[63] - The company’s bank borrowings increased significantly to HKD 32,870,000 in June 2024 from HKD 11,035,000 in December 2023, a rise of 197.5%[61] Employee and Operational Efficiency - The company employed a total of 458 staff, including 32 in R&D and 216 in production in China[54] - Employee costs, including director remuneration, rose to HKD 64,281,000 for the six months ended June 30, 2024, compared to HKD 48,386,000 in the same period of 2023, reflecting an increase of about 33%[76] - The company aims to enhance its operational efficiency and explore potential mergers and acquisitions to drive growth[92] Stock Options and Shareholder Returns - The company has a total of 563,055,000 shares outstanding with a weighted average exercise price of HKD 0.18[95] - The company has a new stock option plan effective for ten years, allowing the board to grant options to eligible participants[92] - The company has not exercised any stock options during the reporting period[94] - The company aims to maintain its ability to continue as a going concern and provide returns to shareholders while supporting stability and development[98]

Financial Performance - Revenue for the year ended December 31, 2023, was HKD 484.7 million, an increase of approximately 10.0% from HKD 440.3 million in 2022[15]. - Gross profit for 2023 was HKD 392.8 million, resulting in a gross margin of 81.0%, compared to 76.1% in 2022[15][16]. - Adjusted EBITDA for 2023 was HKD 99.4 million, up from HKD 66.1 million in 2022, indicating a significant improvement in operational efficiency[15]. - The company reported a pre-tax profit of HKD 75.9 million for 2023, a significant increase from HKD 43.3 million in 2022, marking a successful year of profitability[15]. - The net profit for 2023 was approximately HKD 70.9 million, showing a significant year-on-year increase of 84.04% due to strict cost control measures[36]. - The profit for the year hit a record high of approximately HKD 70.9 million, a significant increase of 84.04% year-on-year, with earnings per share rising to about HKD 1.11, up 82%[68]. - Sales of the flagship product, Jinyin Peptide®, generated approximately HKD 186.0 million, reflecting a 9.8% increase due to expanded hospital networks and digital sales channels[69]. - The revenue from the patented biopharmaceuticals segment was approximately HKD 226.9 million, a 9.2% increase, accounting for 46.8% of total sales[75]. - Other income increased by 57.8% to approximately HKD 13.6 million, driven by growth in the CMO business[82]. Product Development and Innovation - The company launched its fifth self-developed drug, Bo Gu Tai®, which received positive market response shortly after its release[22]. - The company has introduced a new product, a domestically produced pre-filled pen injection of teriparatide, which is expected to outperform existing imported products[22]. - The company launched Skbrella™ FN, a functional skincare ingredient that improves skin repair speed and tolerance, marking its entry into the medical aesthetics industry[24]. - The company is actively developing three additional functional skincare ingredients to diversify its product offerings and revenue sources[24]. - The company has developed two technical platforms, including a synthetic biology platform that could significantly reduce long-term production costs for bioparticles[26]. - The hydrogel technology platform focuses on creating temperature-sensitive hydrogel formulations for epidermal growth factor products, enhancing drug delivery and healing processes[26]. - The company has completed preliminary development of an anti-wrinkle peptide product, with plans for functional validation to follow[59]. - Collagen, which constitutes 25% to 35% of total body protein, is being developed for skincare applications, focusing on hydration and anti-aging[60]. - Microecological skincare products are being developed using synthetic biology techniques, with a project launched in collaboration with the Hong Kong Institute of Nano and Advanced Materials[61]. - Exosomes derived from mesenchymal stem cells (MSCs) are being explored for their regenerative properties in skincare, promoting collagen synthesis and reducing scar formation[62]. Research and Development - Research and development expenses accounted for 7.3% of total revenue in 2023, down from 8.1% in 2022, reflecting improved cost management[15][16]. - The establishment of a new R&D center in Beijing aims to facilitate breakthroughs in product development[25]. - The company continues to focus on R&D in endocrine diseases, ophthalmology, and dermatology, with multiple patented biopharmaceuticals and high-value generics in various stages of development[43]. - The company has doubled its EGF product production capacity and plans to quadruple it by April 2024, enhancing production efficiency and reducing costs[92]. - The synthetic biology technology platform aims to improve the production performance of E. coli, significantly lowering the cost of bioactive peptides[93]. Market Strategy and Expansion - The company aims to expand its market share through strategic partnerships and innovative product offerings in the Chinese healthcare market[5][22]. - The company is preparing for the fourth clinical study of Bogu Tai®, focusing on fracture prevention and pain relief, to enhance its competitive edge[88]. - The market for osteoporosis-related medical expenses is expected to soar to RMB 132 billion by 2035 and RMB 163 billion by 2050, indicating substantial growth opportunities[86]. - The dry eye medication market is expected to exceed RMB 42 billion by 2030, with an impressive CAGR of 28.4%[89]. - The Chinese functional skincare market is projected to reach RMB 122.4 billion by 2028, with a compound annual growth rate (CAGR) of 17.5% from 2023 to 2028[85]. Corporate Governance - The company is committed to maintaining high standards of corporate governance and transparency in its operations[118]. - The board includes independent directors with significant experience in finance and management, ensuring robust governance practices[118][119]. - The company has established procedures for handling and disseminating inside information, adopting a disclosure policy for compliance[166]. - The risk management process includes identifying, assessing, and managing risks that may affect the company's business and operations[163][164]. - The board conducts an annual review of the effectiveness of the risk management and internal control systems through the audit committee[165]. - The company has adopted all applicable corporate governance codes as per the listing rules, demonstrating its commitment to transparency and accountability[125]. Management and Leadership - The company has a strong management team with members holding advanced degrees from prestigious institutions, including Imperial College London and Peking University[113][114]. - The management team has received multiple industry awards, highlighting their leadership and innovation in the biotechnology sector[113]. - The company has appointed Mr. Du Kai as the Chief Financial Officer effective March 31, 2022, bringing over 18 years of financial and tax experience, particularly in the biopharmaceutical industry[122]. - The management team includes experienced professionals with extensive backgrounds in sales, manufacturing, R&D, and clinical research, contributing to the company's strategic goals[121]. - The board consists of seven members, including three executive directors and three independent non-executive directors, ensuring a balanced governance structure[126]. Shareholder Communication - The company maintains effective communication with shareholders through regular financial disclosures and updates on its website[178]. - The company emphasizes the importance of timely and balanced information dissemination to shareholders and potential investors[177]. - The company has audited its shareholder communication policy for the year ending December 31, 2023, and found it to be effectively implemented[181]. - Shareholders have the right to request special meetings if they hold at least 10% of the company's paid-up capital[173]. Future Outlook - The company is focused on expanding its market presence and enhancing its product offerings through strategic partnerships and acquisitions[117]. - The company is committed to enhancing shareholder value through prudent management and strategic decision-making[125].

Financial Performance - The company reported a basic and diluted earnings per share of HKD 35,340,000 for the year ended December 31, 2023, compared to HKD 36,479,000 for the previous year, reflecting a decrease of approximately 3.1%[23] - For the fiscal year ending December 31, 2023, the company's revenue reached approximately HKD 484.7 million, representing a year-on-year growth of 10.1%[33] - The profit for the year amounted to approximately HKD 70.9 million, showing a significant year-on-year increase of 84.04%, marking an important milestone for the research-based biopharmaceutical company[33] - The company achieved a record revenue of approximately HKD 484.7 million for the year ended December 31, 2023, representing a year-on-year growth of 10.1%[49] - Net profit for the year reached approximately HKD 70.9 million, a significant year-on-year increase of 84.04%, attributed to strict cost control measures[49] - Gross profit amounted to approximately HKD 392.8 million, an increase of 17.3% compared to approximately HKD 334.9 million in the previous year, with a gross margin improvement of 4.9 percentage points to 81.0%[125] - Basic earnings per share for 2023 was HKD 1.11, up from HKD 0.61 in 2022, indicating a growth of 81.0%[185] Expenses and Cost Management - The company recognized a total of HKD 1,755,000 in expenses related to auditor remuneration for the year, compared to HKD 1,816,000 in the previous year, indicating a slight decrease of about 3.4%[3] - Research and development expenses capitalized amounted to HKD 51,950,000, down from HKD 53,940,000 in the previous year, a decrease of approximately 3.7%[3] - General and administrative expenses as a percentage of revenue decreased from 10.7% to 9.8%, attributed to the company's ongoing internal control and cost-cutting measures[36] - Research and development expenses as a percentage of revenue decreased to 7.3% in 2023 from 8.1% in 2022[55] - Research and development expenses for the year were HKD 35,576,000, slightly down from HKD 35,781,000 in 2022[185] Revenue Sources and Growth - The total revenue from service income primarily related to entrusted processing business was not specified but is a key focus area for the company[2] - Sales of Pipanpu® and Jinyin Peptide® performed exceptionally well, growing by 15.0% and 9.54% year-on-year, respectively[33] - The flagship product, Jindan Peptide®, generated revenue of approximately HKD 186.0 million, reflecting a year-on-year increase of 9.8%[118] - The revenue from the chemical pharmaceuticals segment was approximately HKD 257.9 million, reflecting a year-on-year increase of 10.9%[124] - The patented biopharmaceuticals segment recorded sales of approximately HKD 226.9 million, a growth of about 9.2% year-on-year, accounting for 46.8% of total sales[123] Assets and Liabilities - The total assets of the group as of December 31, 2023, are approximately HKD 409.99 million, with current assets at about HKD 238.1 million[145] - The group's current liabilities as of December 31, 2023, amount to HKD 114.79 million, resulting in a current liabilities to total assets ratio of 28.0%[145] - Non-current liabilities increased significantly to HKD 38,028 thousand from HKD 7,470 thousand year-over-year[199] - Bank borrowings rose sharply to HKD 30,612 thousand compared to HKD 985 thousand in the previous year[199] - Total equity increased to HKD 257,174 thousand from HKD 194,746 thousand, reflecting a growth of approximately 32%[199] Corporate Governance and Compliance - The company has not declared or proposed any dividends for the year 2023, consistent with the previous year[21] - The board does not recommend the payment of a final dividend for the year ending December 31, 2023, consistent with the previous year[162] - The audit committee consists of three independent non-executive directors and has reviewed the consolidated financial statements for the year ending December 31, 2023[163] - The company has maintained compliance with the corporate governance code applicable as of December 31, 2023[164] Research and Development Initiatives - A new research and development center for green peptide innovative drugs and advanced technologies was established in Beijing, integrating the latest advancements in biological informatics, genetic engineering, and oral formulation technology[36] - The development of oral Uni-GLP-1 has shown superior bioavailability compared to the positive control oral semaglutide, with ongoing preparations for formal animal studies[68] - UB101, a dual-target nanobody, is being developed to treat wet age-related macular degeneration, aiming to overcome the limitations of intravitreal injections[69] - The company is focusing on innovative and patented products in endocrinology, ophthalmology, and dermatology, with multiple leading patented biopharmaceuticals in different stages of development[84] - The group is at the forefront of developing a new temperature-sensitive hydrogel formulation for EGF products, which enhances drug delivery and accelerates wound healing[152] Market Opportunities and Strategic Developments - The company is actively exploring commercialization opportunities for Skbrella™ FN to unlock its full market potential[61] - The market for osteoporosis-related medical expenses is projected to soar to RMB 132 billion by 2035 and RMB 163 billion by 2050, indicating substantial growth potential for Bogu Tai®[134] - The dry eye medication market is anticipated to exceed RMB 42 billion by 2030, with a remarkable CAGR of 28.4%, presenting a significant growth opportunity for the company[137] - The Chinese functional skincare market is projected to reach RMB 122.4 billion by 2028, with a compound annual growth rate of 17.5% from 2023 to 2028[150] Share Repurchase and Investments - The company repurchased 86,000,000 shares at a total cost of HKD 5.167 million, with the highest price per share being HKD 0.069 and the lowest HKD 0.052[29] - A total of 86,000,000 shares were repurchased during the year ending December 31, 2023, with an additional 115,180,000 shares repurchased in January 2024[174] - The company provided a loan of RMB 7.15 million to Guangzhou Taili Biological Pharmaceutical Technology Co., Ltd. for a term of 24 months starting September 19, 2023[179] Legal and Regulatory Matters - The company has not been involved in any significant legal proceedings or arbitration as of December 31, 2023[12] - The sodium diquafosol eye drops application was officially accepted by the drug regulatory authority in January 2024, with expectations for market approval in Q1 2025[95] - The completion of the sale of shares in Huashengyuan is subject to additional time due to new government regulations[181]

Financial Performance - For the first half of 2023, the company's revenue increased significantly by 27.8% year-on-year to approximately HKD 249.9 million, while profit surged by 169.2% to about HKD 39.4 million[14]. - The gross profit for the first half of 2023 was HKD 198.9 million, reflecting a 37.6% increase compared to HKD 144.5 million in the same period last year[26]. - Operating profit rose by 35.0% to HKD 54.7 million, up from HKD 40.5 million in the previous year[26]. - The total comprehensive income for the period was HKD 30.0 million, compared to HKD 6.2 million in the previous year[121]. - Basic and diluted earnings per share were HKD 0.62, up from HKD 0.23 in the same period last year[121]. - The company reported a pre-tax profit of HKD 43,395,000 for the first half of 2023[185]. - The income tax expense for the first half of 2023 was HKD 3,994,000, significantly higher than HKD 650,000 in the previous year[192]. Research and Development - Research and development costs decreased by 51.7% to HKD 11.7 million, compared to HKD 24.3 million in the prior year[26]. - The company is conducting animal studies to further validate the bioavailability of its oral Uni-GLP-1 formulation, which has shown superior efficacy compared to the positive control[41]. - The company is developing innovative technologies to overcome the limitations of current treatments for wet age-related macular degeneration[41]. - The company is focused on biotechnology, particularly in developing and commercializing biological drugs through DNA and other technological research[200]. - Research and development expenses amounted to HKD 23,025,000, slightly down from HKD 24,316,000 in the previous year[189]. Product Development and Launches - The company successfully launched its first advanced skincare raw material product, a recombinant human fibronectin protein, in May 2023, aimed at various skin conditions[15]. - The company is preparing for the launch of its product "Bogu Tai" in the second half of 2023 after completing necessary regulatory approvals[30]. - The second-generation Uni-PTH injection pen, named Bogu Tai, is expected to be approved for market launch in 2023, enhancing patient convenience and safety[63]. - The company is actively exploring commercialization opportunities for the recombinant protein to maximize its market potential[15]. - The company is leveraging synthetic biology to develop a range of new skincare ingredients, including collagen and beauty peptides, for commercialization[45]. Market Trends - The global wound dressing market is expected to reach $24.01 billion by 2028, with a compound annual growth rate (CAGR) of 6.1% from 2021 to 2028[44]. - The Chinese wound dressing market grew from RMB 5.52 billion in 2014 to RMB 13.62 billion in 2018, representing a CAGR of 25.3%[44]. - The Chinese wound dressing market is projected to reach RMB 23.45 billion in 2023, maintaining a CAGR of 11.1% from 2019 to 2023[44]. - The skincare market is experiencing significant growth, with the Chinese beauty medical market expected to exceed RMB 200 billion in 2023, driven by post-pandemic recovery and rising disposable income[55]. - The healthcare market in China is expected to maintain strong growth, with a projected compound annual growth rate of 8.8% from 2023 to 2027, reaching USD 26.8 billion by 2027[103]. Financial Stability and Investments - As of June 30, 2023, the company's cash and bank balances were approximately HKD 95.3 million, with total assets of approximately HKD 311.3 million, up from HKD 292.5 million at the end of 2022[133]. - The total liabilities to total assets ratio as of June 30, 2023, was 25.8%, down from 30.9% at the end of 2022, indicating improved financial stability[133]. - The total equity as of June 30, 2023, is HKD 224,759,000, an increase from HKD 194,746,000 as of December 31, 2022, representing a growth of approximately 15.4%[167]. - The net cash generated from operating activities for the six months ended June 30, 2023, is HKD 30,360,000, compared to HKD 9,547,000 for the same period in 2022, indicating a significant increase of 218.5%[169]. - The company did not engage in any significant investments or plans for major capital assets during the six months ended June 30, 2023[134]. Marketing and Sales - A comprehensive marketing strategy has been developed to ensure the successful market entry of Bogu Tai, including a national press conference planned for Q4 2023 to create significant impact[130]. - The company has established a dedicated marketing department to cover all digital channels, reflecting its commitment to maintaining a leading position in the evolving healthcare sector[131]. - The flagship product, Jin Yin Peptide, generated revenue of approximately HKD 95.9 million, an increase of 31.8% year-on-year, due to the expansion of the hospital network and upgraded production capacity[87]. - The sales of patented biopharmaceuticals reached approximately HKD 118.2 million, a substantial increase of 30.6% compared to the same period last year, accounting for 47.3% of total sales[90]. - The revenue from the chemical pharmaceuticals segment reached approximately HKD 131.8 million, a significant increase of 25.4% compared to the same period last year[91].

Financial Performance - Revenue for the year ended December 31, 2022, was HKD 440.316 million, representing a 24.6% increase from HKD 353.405 million in 2021[13]. - Gross profit for the same period was HKD 334.883 million, with a gross margin of 76.1%, down from 78.4% in the previous year[13][18]. - The company achieved a historical revenue high in 2022, with a year-on-year increase of 24.6% despite challenges from the COVID-19 pandemic[39]. - The company recorded a record revenue of approximately HKD 440.3 million for the year 2022, representing a significant year-on-year growth of 24.6% from HKD 353.4 million in 2021[69]. - The company achieved a net profit of approximately HKD 38.5 million in 2022, a substantial increase of 296.6% compared to a loss of HKD 19.6 million in 2021[70]. - The sales cost increased by 38.0% to approximately HKD 105.4 million in 2022, up from about HKD 76.4 million in 2021, while gross profit rose by 20.9% to approximately HKD 334.9 million[69]. - The gross margin for 2022 was 76.1%, slightly down from 78.4% in 2021[69]. Research and Development - Research and development expenses were HKD 35.781 million, accounting for 8.1% of revenue, a decrease from 14.2% in 2021[13][19]. - The company is focusing on R&D in endocrine diseases, ophthalmology, and dermatology, with multiple patented biopharmaceuticals and high-value generic drugs at various stages of development[44]. - The company is committed to enhancing its R&D capabilities and has partnered with Oran Biomedicine and DotBio to explore new applications for cell-penetrating protein technology[96]. - The company is researching oral delivery innovations for peptide drugs, with the third-generation Uni-PTH product showing promise in enhancing competitiveness in the endocrine field[97]. - The company is developing new products such as sodium diquafosol eye drops, which are expected to provide a new clinical treatment option for dry eye patients in China[91]. Product Development and Market Strategy - The company has two new prescription drugs, Uni-E4 and Uni-PTH, that have completed clinical trials, targeting type 2 diabetes and osteoporosis respectively[10][11]. - The company launched a new product, 博固泰®, expected to receive market approval by September 2023, marking its fifth self-developed drug[26]. - The new drug application for Bogutai® (teriparatide injection) was accepted by the National Medical Products Administration, preparing for entry into the osteoporosis market[41]. - The company is preparing for a national centralized procurement for Pinapu® in April 2023, aiming to secure its position in future procurements[27]. - The product BoguTai® is anticipated to receive market approval by September 2023, aiming to capture a significant share of the projected $81.5 billion osteoporosis market in China by 2031[92]. Market Performance - The company successfully captured nearly 50% market share for its product, Pinapu®, significantly outperforming competitors in sales[27]. - The flagship product, Jin Yin Peptide®, generated revenue of approximately HKD 169.4 million in 2022, a slight decline of 0.6% from HKD 170.5 million in 2021[72]. - The proprietary biological drugs generated sales of approximately HKD 207.8 million, a growth of 0.5% compared to the previous year, accounting for 47.2% of total sales[78]. - The proprietary chemical drugs, including Pinafu® and Boshu Tai®, achieved revenue of approximately HKD 232.5 million, a substantial increase of 58.5% year-on-year[79]. Corporate Governance - The board consists of seven members, including three executive directors and three independent non-executive directors, ensuring a balanced governance structure[139]. - The company has adopted all applicable corporate governance codes as per the listing rules, demonstrating its commitment to transparency and accountability[138]. - The independent non-executive directors are confirmed to meet independence criteria, ensuring unbiased judgment in strategic decisions[141]. - The company emphasizes maintaining and improving corporate governance quality to enhance investor confidence and ensure stable growth[137]. - The board is responsible for determining the company's corporate governance policies and ensuring compliance with legal and regulatory requirements[170]. Financial Health and Ratios - The cash ratio improved to 1.09 from 0.91, and the current ratio increased to 2.22 from 2.18[15]. - The debt-to-equity ratio decreased to 50.2% from 53.5%[15]. - Total asset turnover improved to 150.6% from 132.1%[15]. - As of December 31, 2022, the company's cash and bank balances were approximately HKD 98.22 million, with total assets of approximately HKD 292.47 million[99]. - The company's current liabilities as of December 31, 2022, were approximately HKD 90.26 million, resulting in a current liabilities to total assets ratio of 30.9%[99]. Management and Leadership - The company has a strong management team with members holding advanced degrees from prestigious institutions, including Peking University and the University of Hartford[126][127]. - The management team has a combined experience of over 100 years in various sectors, including finance, consulting, and corporate governance[128][130]. - The company appointed Mr. Liang Guolong as Executive Director and Chairman of the Board since January 13, 2017, with extensive experience in investment banking and biotechnology[122]. - Mr. Zhao Zhigang has been the CEO since April 8, 2019, and has over 20 years of experience in corporate finance and auditing, previously serving as CFO for several listed companies[124]. - The company has appointed Mr. Du Kai as the Chief Financial Officer, effective March 31, 2022, bringing over 17 years of financial and tax experience, particularly in the biopharmaceutical industry[132]. Employee and Talent Management - The company employed 370 staff members as of December 31, 2022, with a focus on competitive compensation to attract and retain talent[101]. - The company has achieved gender diversity among employees, with a male-to-female ratio improving from 70:100 last year to 100:100[181]. - The board currently consists entirely of male members, but the company aims to appoint female directors to meet diversity requirements by December 31, 2024, targeting a female representation of over 10%[180]. Compliance and Ethics - The company emphasizes high standards of business ethics and integrity, requiring all employees to adhere to a long-established code of conduct[198]. - The group has established business codes for all manufacturers and suppliers, ensuring safe and healthy workplaces and fair recruitment practices[198]. - The company closely monitors compliance with the codes of conduct set by major licensors and customers for its manufacturers and suppliers[198]. Future Outlook - The company anticipates that the pharmaceutical and healthcare industry in China will continue to thrive due to aging population, domestic substitution, and supportive policies[87]. - The company plans to continue focusing on gender diversity among employees to enhance its future competitiveness[181]. - The company is committed to ongoing research and development of new products and technologies to drive future growth[130].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就 因本公佈全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度 之 末 期 業 績 公 佈 截至二零二二年十二月三十一日止年度摘要 • 截至二零二二年十二月三十一日止年度（「年內」），本集團營業額創 新高，達到440.3百萬港元，按年（「按年」）顯著增長24.6%。 • 年 內，本 集 團 扭 虧 為 盈，盈 利38.5百 萬 港 元，按 年 大 幅 增 長296.6%， 成為一家研究型生物製藥公司的重要里程碑。 • 匹 納 普®及 及 博 舒 泰®的 銷 售 表 現 異 常 出 色，按 年 分 別 增 長51.2%及 292.5%。 ...

Financial Performance - For the six months ended June 30, 2022, the company reported revenue of HKD 195,578,000, representing a year-on-year increase of 24.6% from HKD 156,984,000[9]. - Gross profit for the same period was HKD 144,507,000, with a gross margin of 73.9%, down from 79.3% in the previous year[9]. - The company achieved a significant increase in profit before tax, reaching HKD 15,289,000, a 429% rise compared to HKD 2,890,000 in the prior year[12]. - The company achieved a net profit of approximately HKD 14.6 million, a substantial increase of 663.6% compared to HKD 1.9 million in the first half of 2021[59]. - The gross margin for the first half of 2022 was 73.9%, down from 79.3% in the same period of 2021[58]. - The company reported a total comprehensive income for the period of HKD 6,226,000, compared to HKD 4,168,000 in the previous year, indicating a growth of 49.4%[118]. - The company reported a loss of HKD 2,008,161,000 as of June 30, 2022, which reflects a slight decrease from the previous year's loss of HKD 2,010,078,000[128]. Research and Development - Research and development expenses amounted to HKD 24,316,000, accounting for 12.4% of total revenue, a slight decrease from 13.6% in the previous year[9]. - The company is focusing on R&D in endocrine diseases, ophthalmology, and dermatology, with multiple patented biopharmaceuticals and high-value generics in various stages of development[26]. - The company’s R&D expenses grew by 13.8% to approximately HKD 24.3 million, reflecting its commitment to innovation and development[58]. - The company is committed to developing a third-generation oral Uni-PTH, which currently has no market equivalents, enhancing its competitive edge in the endocrine field[92]. - The company is preparing to develop an oral GLP-1 formulation, which has shown superior effects in animal tests compared to existing products on the market[92]. Product Development and Market Expansion - The company launched four products in the market, including Jinyin Peptide® and Boshutai®, enhancing its product portfolio[16]. - The company successfully won procurement bids for "Boshutai" (Acarbose Tablets) in 13 provinces in China, providing an opportunity to rapidly expand its hospital market share[25]. - The company is expanding its Suzhou production capacity to meet the anticipated high demand for "Boshutai" and is preparing to develop Diquafosol Sodium Eye Drops as part of its high-value generics strategy[25]. - The anticipated launch of Bogu Tai (Teriparatide injection) is expected to provide better drug options for patients and tap into the growing osteoporosis market, projected to grow from USD 21.2 billion in 2021 to USD 81.5 billion by 2031[85]. - The company is exploring various ophthalmic products to fully utilize the capacity of the new BFS production line, including a high-value generic eye drop for dry eye syndrome, leveraging API cost advantages[89]. Market Outlook - The Chinese pharmaceutical market is projected to reach RMB 1.868 trillion by 2022, indicating strong growth potential for the company[15]. - The global wound dressing market is expected to reach $24.01 billion by 2028, with a compound annual growth rate (CAGR) of 6.1% from 2021 to 2028[41]. - The Chinese wound dressing market has grown from RMB 5.52 billion in 2014 to RMB 13.62 billion in 2018, with a CAGR of 25.3%, and is projected to maintain an 11.1% CAGR, reaching RMB 23.45 billion by 2023[41]. - The company is optimistic about the prospects of the Chinese pharmaceutical and medical aesthetics markets, which are expected to create significant value for established enterprises[15]. Financial Position and Liquidity - The company maintained a cash ratio of 1.07 and a current ratio of 2.62, indicating improved liquidity compared to 0.91 and 2.18, respectively, in the previous year[9]. - As of June 30, 2022, the company's cash and bank deposits amounted to approximately HKD 81.33 million, with total assets of about HKD 262.48 million[93]. - The company's total liabilities to total assets ratio decreased to 31.2% as of June 30, 2022, down from 34.9% at the end of 2021[93]. Corporate Strategy - The company plans to upgrade its business model to a "four-wheel drive" model focusing on high-value generics, biological innovations, new skincare raw materials, and CMO business[79]. - The company is collaborating with a cosmetics partner to develop competitive skincare raw materials, aiming for commercialization in the first half of 2023[83]. - The company is leveraging its research ecosystem and bioprocessing platform to rapidly commercialize new skincare products, including collagen and stem cell exosome products[43]. Employee and Operational Insights - The company employs 340 staff members, including 32 in R&D, 170 in production, and 78 in commercial offices in China, with competitive compensation to attract and retain talent[105]. - The company has issued 6,364,768,147 shares as of June 30, 2022, with a total capital of HKD 63,648,000[183].